Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• MicroRNA-21 (miR-21) is an oncogene implicated in multiple myeloma pathogenesis.
• The therapeutic potential of ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, in multiple myeloma remains underexplored.

Purpose of the Study:

• To investigate the role of miR-21 in multiple myeloma progression.
• To evaluate the effect of ibrutinib on miR-21 expression and its underlying mechanisms in multiple myeloma.

Main Methods:

• Analysis of miR-21 expression in relation to multiple myeloma progression.
• Treatment of multiple myeloma cells with ibrutinib.
• Assessment of signaling pathways, including nuclear factor-κB (NF-κB) and signal transducer and activator of transcription 3 (STAT3), affected by ibrutinib.

Main Results:

• miR-21 expression correlates with multiple myeloma progression, identifying it as an oncogenic marker.
• Ibrutinib treatment significantly reduces miR-21 expression in multiple myeloma cells.
• Ibrutinib's attenuation of miR-21 is mediated through the inhibition of NF-κB and STAT3 signaling pathways.

Conclusions:

• miR-21 is a key oncogenic factor in multiple myeloma.
• Ibrutinib demonstrates potential as a novel therapeutic agent for multiple myeloma by targeting miR-21 expression via NF-κB and STAT3 inhibition.
• Further research is warranted to elucidate the full therapeutic potential of ibrutinib in multiple myeloma.